HK1258415A1 - 作為致癌基因 erg 的抑制劑的偶氮苯酚 - Google Patents

作為致癌基因 erg 的抑制劑的偶氮苯酚

Info

Publication number
HK1258415A1
HK1258415A1 HK19100848.3A HK19100848A HK1258415A1 HK 1258415 A1 HK1258415 A1 HK 1258415A1 HK 19100848 A HK19100848 A HK 19100848A HK 1258415 A1 HK1258415 A1 HK 1258415A1
Authority
HK
Hong Kong
Prior art keywords
azophenols
oncogene inhibitors
erg
erg oncogene
inhibitors
Prior art date
Application number
HK19100848.3A
Other languages
English (en)
Inventor
Albert L Dobi
Clifton Dalgard
Shiv Srivastava
Original Assignee
Henry M Jackson Found Advancement Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found Advancement Military Medicine Inc filed Critical Henry M Jackson Found Advancement Military Medicine Inc
Publication of HK1258415A1 publication Critical patent/HK1258415A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/04Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK19100848.3A 2015-09-10 2019-01-17 作為致癌基因 erg 的抑制劑的偶氮苯酚 HK1258415A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562216839P 2015-09-10 2015-09-10
PCT/US2016/051098 WO2017044844A1 (en) 2015-09-10 2016-09-09 Azophenols as erg oncogene inhibitors

Publications (1)

Publication Number Publication Date
HK1258415A1 true HK1258415A1 (zh) 2019-11-08

Family

ID=58240304

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100848.3A HK1258415A1 (zh) 2015-09-10 2019-01-17 作為致癌基因 erg 的抑制劑的偶氮苯酚

Country Status (7)

Country Link
US (3) US10238639B2 (zh)
EP (1) EP3347001B1 (zh)
JP (1) JP6865174B2 (zh)
AU (1) AU2016319111B2 (zh)
CA (1) CA2981188C (zh)
HK (1) HK1258415A1 (zh)
WO (1) WO2017044844A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2981188C (en) 2015-09-10 2024-05-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Azophenols as erg oncogene inhibitors
US20230382862A1 (en) * 2020-06-19 2023-11-30 Sanjay Malhotra Erg oncogene inhibitors
CN113616645A (zh) * 2021-08-27 2021-11-09 深圳先进技术研究院 一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用
EP4440594A2 (en) * 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0738075B2 (ja) 1986-12-23 1995-04-26 住友化学工業株式会社 新規なフオトレジスト組成物
WO1998029257A1 (fr) 1996-12-27 1998-07-09 Tdk Corporation Support d'enregistrement optique
US8143232B2 (en) * 2009-03-03 2012-03-27 The Regents Of The University Of Michigan Gene fusion targeted therapy
CA2925922C (en) * 2013-09-30 2023-03-21 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
CA2981188C (en) 2015-09-10 2024-05-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Azophenols as erg oncogene inhibitors

Also Published As

Publication number Publication date
CA2981188C (en) 2024-05-28
JP2018526320A (ja) 2018-09-13
WO2017044844A1 (en) 2017-03-16
US20180169074A1 (en) 2018-06-21
EP3347001A4 (en) 2019-05-08
AU2016319111B2 (en) 2021-05-06
US11648239B2 (en) 2023-05-16
CA2981188A1 (en) 2017-03-16
US20190336485A1 (en) 2019-11-07
US10238639B2 (en) 2019-03-26
EP3347001A1 (en) 2018-07-18
US20210299106A1 (en) 2021-09-30
EP3347001B1 (en) 2023-07-26
AU2016319111A1 (en) 2017-10-19
JP6865174B2 (ja) 2021-04-28

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HRP20181899T1 (hr) Biaril inhibitori kinaze
IL254187A0 (en) beta-tgf inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL251932B (en) Benzylpropargyl ether as nitrification inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
GB201403536D0 (en) Inhibitor compounds
GB201513481D0 (en) Inhibitor compounds
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201505658D0 (en) Inhibitor compounds
GB201501004D0 (en) Inhibitors
HK1258415A1 (zh) 作為致癌基因 erg 的抑制劑的偶氮苯酚
GB201612860D0 (en) Inhibitors
HK1251572A1 (zh) 作為ddr1抑制劑的三氮雜-螺癸酮類化合物
GB201520949D0 (en) Inhibitors
GB201401005D0 (en) Inhibitor
PT3322724T (pt) Inibidores da il-26
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201522453D0 (en) Inhibitor compounds
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201500644D0 (en) Inhibitor compounds
GB201418154D0 (en) Inhibitors